

PCT

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
2488.017

In Re Application Of: Groner et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/540,402	06/23/2005	Unassigned	23405	Unassigned	8368

Title: **METHODS FOR EVALUATING GENETIC SUSEPTIBILITY AND THERAPY FOR CHRONIC INFLAMMATORY DISEASES**



Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);

OR

☐ the fee set forth in 37 CFR 1.17(p).

00 7 11 30 PM 2:00


TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
2488.017

In Re Application of: Groner et al.

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/540,402	06/23/2005	Unassigned	23405	Unassigned	8368

Title: **METHODS FOR EVALUATING GENETIC SUSEPTIBILITY AND THERAPY FOR CHRONIC INFLAMMATORY DISEASES**



Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fa

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on

January 24, 2006

(Date)

Jeff Rothenberg

Signature of Person Mailing Correspondence

Jeff Rothenberg

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.


Jeff Rothenberg

Signature

Dated: January 24, 2006

Jeff Rothenberg, Esq.
Reg. No. 26,429
Heslin Rothenberg Farley & Mesiti P.C.
5 Columbia Circle
Albany, NY 12203
Telephone: (518) 452-5600
Facsimile: (518) 452-5579

CC:

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION (USE SEVERAL SHEETS IF NECESSARY) 	ATTY DOCKET NO. 2488.017	SERIAL NO. 10/540,402
	APPLICANT(S) GRONER ET AL.	
	FILING DATE 06/23/2005	GROUP UNASSIGNED

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION		
							NO	YES	ABSTRACT

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

BA	BANGSOW et al. The RUNX3 gene-sequence, structure and regulated expression. Gene. November 2001, Vol. 279, pages 221-232. See entire document.
BB	TANIUCHI et al. Differential Requirements for RUNX proteins in CD4 Repression and Epigenetic Silencing during T Lymphocyte Development. Cell. November 2002, Vol. 111, pages 621-633. See entire document.
BC	LEVANON et al. RUNX3 knockouts and stomach cancer. EMBO. June 2003, Vol. 4, pages 560-564.
BD	ITO et al. RUNX3 transcription factors as key targets of TGF-beta superfamily signaling. Current Opinion In Genetics & Development. February 2003, Vol. 13, pages 43-47. See entire document.
BE	FAINARU et al. RUNX3 regulates mouse TGF-beta-mediated dendritic cell function and its absence results in airway inflammation. EMBO. February 2004, Vol. 23, pages 969-979.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial here if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	